Objectives

The non-steroidal anti-inflammatory drug etoricoxib is the most highly selective inhibitor of cyclooxygenase-2 available (344:1) and has been approved for postoperative pain therapy following dental interventions in Europe. At clinically relevant doses it has been reported to only have marginal effects on the velocity of orthodontic tooth movement (OTM). Its effects on associated dental root resorptions, osteoclastogenesis, trabecular number in the alveolar bone and periodontal bone loss during OTM, however, have not yet been investigated.

Material and methods

40 male Fischer344 rats were divided into four groups: 1.5 ml tap water/day p.o. (control, 1), additional 7.8 mg/kg/day etoricoxib (normal dose) for three (2) or seven (3) days/week and 13.1 mg/kg/day (high dose) for seven days/week, respectively (4). After a week of premedication, OTM in anterior direction of the first left upper molar was performed for 28 days by means of a nickel-titanium coil spring (0.25 N). We quantified OTM-associated dental root resorptions, osteoclastogenesis, trabecular number and periodontal bone loss by histomorphometrical, histochemical and μCT analyses of the disected tooth-bearing upper jaw sections.

Results

After 28 days of OTM, associated reduction of trabecular number seemed to be slightly alleviated by high doses of etoricoxib, whereas no significant other etoricoxib effects in the doses administered could be detected regarding OTM-induced or -associated dental root resorptions, osteoclastogenesis or periodontal bone loss.

Conclusions

Dental root resorptions, osteoclastogenesis and periodontal bone loss during OTM in rats were not significantly affected by etoricoxib in the clinically relevant dosages investigated with only a slight inhibitory effect on bone remodelling to be expected at high dosages. Etoricoxib is therefore not suitable for the prevention of these detrimental effects, but could be a suitable analgesic during OTM, as it has been reported not to affect tooth movement.

中文翻译：

---

NSAID依托昔布对正畸牙齿运动副作用的影响。

目标

非甾体类抗炎药依托考昔是环氧合酶2选择性最强的抑制剂（344：1），在欧洲进行牙科干预后已被批准用于术后疼痛治疗。据报道，在临床上相关剂量下，其对正畸牙齿移动速度（OTM）的影响很小。然而，尚未研究其对OTM期间相关的牙根吸收，破骨细胞生成，牙槽骨中小梁数目和牙周骨丢失的影响。

材料与方法

40只Fischer344雄性大鼠分为四组：1.5 ml /天po口服水（对照组，1只），另外7.8 mg / kg / day依托昔布（正常剂量），三周（2）或七（3）天/周，以及13.1周mg / kg /天（高剂量），分别为7天/周（4）。在一周的用药前，通过镍钛螺旋弹簧（0.25 N）在左上侧第一磨牙的前方向进行OTM处理28天。我们通过解剖切齿的上颌骨部分的形态计量学，组织化学和μCT分析，量化了与OTM相关的牙根吸收，破骨细胞生成，小梁数和牙周骨损失。

结果

OTM 28天后，高剂量的依托昔布似乎可以稍微缓解相关的骨小梁数目减少，但是在OTM诱导或相关的牙根吸收，破骨细胞生成或牙周骨方面，未发现其他依托昔布的明显剂量作用失利。

结论

在依托考昔研究的临床相关剂量下，大鼠在OTM期间的牙根吸收，破骨细胞生成和牙周骨损失并未受到显着影响，在高剂量下预期对骨重塑只有轻微的抑制作用。因此，Etoricoxib不适合预防这些有害作用，但可能已成为OTM期间的合适止痛药，因为据报道它不影响牙齿运动。